1 any fully expressed, progressive infections (kala-azar).

2 ses that includes visceral leishmaniasis, or Kala Azar.

3  prevalence and mortality reported levels of Kala-azar.

4 l in treating T cell-deficient patients with kala-azar.

5  have committed to reducing the incidence of kala-azar, a clinical manifestation of visceral leishman

6 ate, could have a key role in the control of kala-azar, and prevent its resurgence when paired with t

7 nosing patients before the onset of clinical kala-azar (before 14 days fever), and show that this cou

8 timing of use and accuracy of diagnostics in kala-azar control and elimination.

9                                         Post kala-azar dermal leishmaniasis (PKDL), a cutaneous seque

10  patients with maculopapular or nodular post-kala-azar dermal leishmaniasis (PKDL).

11 obtained from healthy, healed VL (HVL), post kala-azar dermal leishmaniasis(PKDL) and VL subjects.

12  was clinical visceral leishmaniasis or post-kala-azar dermal leishmaniasis.

13  (2003) and five (2005) of the most affected Kala-azar districts had been classified as low-risk when

14 ment are important missing components of the kala-azar elimination program.

15 responses do not appear to develop in Indian kala-azar; instead, there is an initial mixed Th1-Th2 ce

16                      Visceral leishmaniasis (kala-azar, KA) is the most severe form of leishmaniasis,

17 gh frequency of treatment failures in Indian kala-azar might be due to infection with antimony-resist

18                                             "Kala-azar" (or Indian Visceral Leishmaniasis) is a vecto

19 tor in the failure of metalloid treatment in kala-azar patients infected with antimony-resistant Leis

20 ve expressions for, and compute estimates of Kala-azar's reproduction numbers, an indirect measure of

21  patients with cutaneous, visceral, and post-kala azar visceral leishmaniasis indicated that a majori